Search
for
Sort by
Research 30 of 36
- Synthesis and application of clinically approved small-molecule drugs targeting androgen receptor
- Antiandrogens
- Editorial: Androgen-dependent diseases and their treatment
- Hétérogénéité tumorale du cancer de la prostate et infection par le SARS-CoV2 : une relation complexe impliquant les vésicules extracellulaires et le récepteur des androgènes
- Androgen receptor modulators: a review of recent patents and reports (2012-2018)
- Computational Evaluation of Dibenzo Compounds as Potential Dual Inhibitors of Androgen Receptor and 5α-Reductase
- Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies
- Are sex discordant outcomes in COVID-19 related to sex hormones?
- Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study
- COVID‐19, androgens, and androgenic alopecia
- Androgen Receptor Ligands: Agonists and Antagonists
- Sexual dimorphism of COVID-19 inspires drug repositioning and host-targeting immunotherapy for viral pneumonia
- Hair Loss and Androgen’s Role in the Era of COVID-19
- COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology
- Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review
- Allosteric interactions prime androgen receptor dimerization and activation
- Enhanced ex vivo skin retention of bicalutamide using a nano-in-micro composite: Drug-loaded lipid vesicles in a dissolving microarray patch
- Bicalutamide: A review
- Design, synthesis and anti-tumor evaluation of novel thiohydantoin congeners as androgen receptor antagonists with in vivo study.
- Table_2.docx
- Table_1.docx
- Androgen sensitivity gateway to COVID‐19 disease severity
- Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”
- Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review
- Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
- Do Anti-androgens Have Potential as Therapeutics for COVID-19?
- Analyzing the role of ACE2, AR, MX1 and TMPRSS2 genetic markers for COVID-19 severity
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- Antiandrogens as Therapies for COVID-19: A Systematic Review
- Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients